These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 15553600)

  • 1. Prescription of statins to dyslipidemic patients affected by liver diseases: a subtle balance between risks and benefits.
    Anfossi G; Massucco P; Bonomo K; Trovati M
    Nutr Metab Cardiovasc Dis; 2004 Aug; 14(4):215-24. PubMed ID: 15553600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma.
    Calderon RM; Cubeddu LX; Goldberg RB; Schiff ER
    Mayo Clin Proc; 2010 Apr; 85(4):349-56. PubMed ID: 20360293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor use in chronic liver disease: a therapeutic controversy.
    Tzefos M; Olin JL
    J Clin Lipidol; 2011; 5(6):450-9. PubMed ID: 22108148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of statins: effects on muscle and the liver.
    Vasudevan AR; Hamirani YS; Jones PH
    Cleve Clin J Med; 2005 Nov; 72(11):990-3, 996-1001. PubMed ID: 16315438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
    Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF
    Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective study of hepatic safety of statins used in very elderly patients.
    Guo M; Zhao J; Zhai Y; Zang P; Lv Q; Shang D
    BMC Geriatr; 2019 Dec; 19(1):352. PubMed ID: 31842780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential role of statins in treating liver disease.
    Imprialos KP; Stavropoulos K; Doumas M; Skalkou A; Zografou I; Athyros VG
    Expert Rev Gastroenterol Hepatol; 2018 Apr; 12(4):331-339. PubMed ID: 29431526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Eslami L; Merat S; Malekzadeh R; Nasseri-Moghaddam S; Aramin H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008623. PubMed ID: 24374462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Considerations for safe use of statins: liver enzyme abnormalities and muscle toxicity.
    Gillett RC; Norrell A
    Am Fam Physician; 2011 Mar; 83(6):711-6. PubMed ID: 21404982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid targets during statin treatment in dyslipidemic patients affected by nonalcoholic fatty liver disease.
    Maroni L; Guasti L; Castiglioni L; Marino F; Contini S; Macchi V; De Leo A; Gaudio G; Tozzi M; Grandi AM; Cosentino M; Venco A
    Am J Med Sci; 2011 Nov; 342(5):383-7. PubMed ID: 21629037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
    Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
    Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An assessment by the Statin Liver Safety Task Force: 2014 update.
    Bays H; Cohen DE; Chalasani N; Harrison SA; The National Lipid Association's Statin Safety Task Force
    J Clin Lipidol; 2014; 8(3 Suppl):S47-57. PubMed ID: 24793441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HMG CoA reductase inhibitors (statins) for dialysis patients.
    Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Nigwekar SU; Hegbrant J; Strippoli GF
    Cochrane Database Syst Rev; 2013 Sep; 2013(9):CD004289. PubMed ID: 24022428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Change in ALT levels after administration of HMG-CoA reductase inhibitors to subjects with pretreatment levels three times the upper normal limit in clinical practice.
    Kim H; Lee H; Kim TM; Yang SJ; Baik SY; Lee SH; Cho JH; Lee H; Yim HW; Choi IY; Yoon KH; Kim HS
    Cardiovasc Ther; 2018 Jun; 36(3):e12324. PubMed ID: 29464863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of statins in patients with chronic hepatitis C.
    Andrus MR; East J
    South Med J; 2010 Oct; 103(10):1018-22; quiz 1023. PubMed ID: 20818300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?
    Evans M; Rees A
    Drug Saf; 2002; 25(9):649-63. PubMed ID: 12137559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse events of statin-fenofibric acid versus statin monotherapy: a meta-analysis of randomized controlled trials.
    Geng Q; Ren J; Chen H; Lee C; Liang W
    Curr Med Res Opin; 2013 Mar; 29(3):181-8. PubMed ID: 23323878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HMG CoA reductase inhibitors (statins) for kidney transplant recipients.
    Navaneethan SD; Perkovic V; Johnson DW; Nigwekar SU; Craig JC; Strippoli GF
    Cochrane Database Syst Rev; 2009 Apr; (2):CD005019. PubMed ID: 19370615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety issues with statin therapy.
    Talbert RL
    J Am Pharm Assoc (2003); 2006; 46(4):479-88; quiz 488-90. PubMed ID: 16913392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluvastatin and hepatic reactions: a signal from spontaneous reporting in Italy.
    Conforti A; Magro L; Moretti U; Scotto S; Motola D; Salvo F; Ros B; Leone R
    Drug Saf; 2006; 29(12):1163-72. PubMed ID: 17147462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.